Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump (BIG LEAP)
Type1 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Type1 Diabetes Mellitus focused on measuring Continuous Glucose Monitoring, CGM, Continuous Subcutaneous Insulin Infusion
Eligibility Criteria
Inclusion Criteria:
- Male and female patients > 18 years of age with type 1 diabetes using CSII with any pump for > 12 months.
- Females must be using adequate contraception, defined as oral contraceptive pill, barrier method of contraception, or surgical method (tubal ligation or hysterectomy).
- Good glycemic control (HbA1c < 8.0%).
- Patients are experienced in carbohydrate counting, evidenced by pump downloads showing frequent meal boluses with realistic carbohydrate entries, few over-rides of the pump bolus calculator, few to no omitted boluses (at least 3 boluses per day), and post-meal glucose levels generally below 200 mg/dl indicating accurate carbohydrate assessment.
- Patients are regular (>85% of time) users of the Dexcom G5 or G6 CGM.
- Pump download confirms correct use of insulin pump features, including appropriate use of bolus calculator with minimal overrides, entering carbohydrate content of meals, at least 3 boluses taken per day, appropriate use of correction boluses, and infusion set changes every 2 to 3 days.
- No serious comorbidities including: retinopathy requiring active intervention, eGFR < 30, CV event within the previous 6 months, active malignancy with ongoing treatment, any condition requiring chronic use of systemic glucocorticoids, or any other condition which in the opinion of the investigator would interfere with the subject's ability to comply with the study protocol or acutely affect insulin requirements.
- Able to comply with study protocol.
Ability to provide written informed consent prior to any study-related procedures.
-
Exclusion Criteria:
- Subjects with type 2 diabetes.
- Subjects with HbA1c > 8.0%
- Subjects not using CSII and CGM (ie, on MDI)
- Subjects inexperienced in the use of CSII, or whose pump download shows poor utilization of bolus calculator features, ie fewer than 2 boluses per day, lack of correction boluses, frequent overrides of the recommended boluses, unrealistic carbohydrate entries (suggestive of under-bolusing), not changing infusion set at least every 3 days, or other evidence of poor insulin pump usage.
- Subjects inexperienced in or not regular users (>85% of time) of Dexcom G5 or G6 CGM
- Subjects who are using a Medtronic pump with low blood glucose suspend who are unwilling to use the Dexcom CGM or to disengage the low blood glucose suspend feature of the pump.
- Use of any other CGM than Dexcom G5 or G6.
- Serious concomitant illness.
- Females unwilling to use adequate contraception, intending to become pregnant, or breastfeeding.
- Known or suspected allergy to study products, their excipients or related products.
- Previous participation in this trial. Note: subjects who screen fail because of A1c may rescreen once if, in the opinion of the investigator, the HbA1c was explainable (ie, recent steroid injection or illness, etc) and atypical for the subject.
- Hypoglycemic unawareness.
Episode of severe hypoglycemia (requiring assistance for treatment) within the previous 90 days.
-
Sites / Locations
- Mountain Diabetes and Endocrine Center
Arms of the Study
Arm 1
Arm 2
No Intervention
Active Comparator
NovoLog®-only
Novolog® and Tresiba® Group
In the aspart-Only group, the subject will only take aspart through the their pump. This study population will have an established expertise in diabetes self-management with previous knowledge of insulin pump therapy and Dexcom Continuous Glucose Monitoring (CGM). Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses. Aspart is put into their pump and delivered to their body through a small tube placed under your skin. In this NovoLog®-only treatment group, the subject will take aspart with each meal while your pump also gives you a slow, continuous dose of aspart for basal insulin. This treatment group is very similar (or even identical) to the treatment the subject was receiving prior to starting the study.
This study population will have an expertise in diabetes self-management with their insulin pump and Dexcom CGM. In the Novolog® and Tresiba® group, the subject will still take aspart via their pump for meals and correction boluses, but they will reduce the slow trickle (basal insulin) programmed in their pump to almost zero. Instead of receiving their normal basal insulin via CSII, the subject will injected degludec once or twice daily from an insulin pen for your basal insulin.